文献速递间质性肺疾病

婴儿持续性呼吸急促/婴儿神经内分泌细胞增生症的欧洲多中心管理及长期结局

Management and Long-Term Outcomes of Persistent Tachypnea of Infancy/Neuroendocrine Cell Hyperplasia of Infancy: A European Multicenter Retrospective Study.
PubMed 文献 · Chest · 2026-02-11

该欧洲多中心回顾性研究纳入17国73中心378例PTI/NEHI患儿,诊断中位年龄9个月,治疗以氧疗(75.9%)、吸入支气管舒张剂和/或吸入糖皮质激素(62.4%)为主,各国治疗策略差异显著(P < .05);长期随访显示症状随年龄改善,但部分患者至青春期仍有残留异常。

要点

  • PTI/NEHI患儿诊断中位年龄9个月,氧疗是最常见干预(75.9%)。
  • 各国治疗策略存在显著差异(P < .05),亟需循证指南。
  • 长期预后总体良好,但部分患者至青春期仍有残留症状和检查异常。

核心结论

  • 欧洲各国对PTI/NEHI的治疗策略存在显著差异,凸显制定循证指南的必要性。
  • 长期预后总体良好,但部分患者残留症状,需持续随访。

研究设计与样本

  • 欧洲多中心、回顾性、观察性研究,纳入17国73中心378例PTI/NEHI患儿。
  • 诊断中位年龄9个月(IQR 6-13个月),男性占63.5%(240/378)。
  • 对贡献至少10例患者的国家间治疗策略进行比较。

主要发现

  • 治疗包括氧疗(75.9%)、吸入支气管舒张剂和/或吸入糖皮质激素(62.4%)、全身糖皮质激素(37.0%)、营养支持(33.8%)。
  • 接受氧疗者中53.6%(154/287)已撤氧,撤氧中位年龄24个月(IQR 16-36个月)。
  • 各国治疗实践差异显著(P < .05)。
  • 48.9%(185/378)有纵向数据,中位随访19个月(IQR 16-57个月),症状比例随时间下降,4岁时改善最明显。
  • 部分患者至青春期仍有持续低氧血症、湿啰音、运动不耐受及影像和肺功能异常。

临床怎么用

  • 氧疗是PTI/NEHI主要治疗手段,撤氧中位年龄24个月可供参考。
  • 应认识到各国治疗差异大,临床决策需个体化并结合随访。
  • 长期随访应关注残留低氧、湿啰音、运动不耐受及影像和肺功能异常。

局限性

  • 回顾性观察性设计,纵向数据仅覆盖48.9%患者。
  • 随访时间有限(中位19个月),长期结局数据仍不完整。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Persistent tachypnea of infancy (PTI), also known as neuroendocrine cell hyperplasia of infancy (NEHI), represents 1 of the most common childhood interstitial lung diseases. Despite its frequency, standardized management protocol is lacking, and long-term outcome data remain limited. RESEARCH QUESTION: What treatment is used for patients with PTI/NEHI, how does clinical management vary across European countries, and what are the long-term outcomes in affected patients? STUDY DESIGN AND METHODS: This was a European multicenter, retrospective, observational study. Clinical characteristics, therapeutic interventions, and long-term follow-up data were collected and analyzed. Treatment strategies were compared among countries that contributed at least 10 patients. RESULTS: A total of 378 children (63.5% male [240 of 378]) from 73 centers across 17 countries were enrolled, with a median age at diagnosis of 9 months (interquartile range [IQR], 6-13 months). Therapeutic interventions included oxygen supplementation (75.9% [287 of 378]); inhaled bronchodilators, inhaled glucocorticoids, or both (62.4% [236 of 378]); systemic glucocorticoids (37.0% [140 of 378]); and nutritional support (33.8% [128 of 378]). Of the children who received oxygen therapy, 53.6% (154 of 287) were reported to have been weaned off, with a median age at weaning of 24 months (IQR, 16-36 months). Marked variability in treatment practices was observed across participating countries (P < .05). Longitudinal data were available for 48.9% of patients (185 of 378) with a median follow-up of 19 months (IQR, 16-57 months). The proportion of symptomatic children declined over time, with the most marked improvement observed at 4 years of age. Resolution of imaging and pulmonary function abnormalities also was reported; however, a subset of patients continued to demonstrate persistent hypoxemia, crackles, and exercise intolerance, as well as abnormal imaging and pulmonary function test findings into adolescence. INTERPRETATION: Our results show that significant differences in treatment strategies for PTI/NEHI were observed across European countries, highlighting the need for evidence-based guidelines. Although long-term prognosis generally is favorable, residual symptoms remain in some patients, warranting continued follow-up.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Marczak H, Krenke K, Griese M, et al. Management and Long-Term Outcomes of Persistent Tachypnea of Infancy/Neuroendocrine Cell Hyperplasia of Infancy: A European Multicenter Retrospective Study. Chest. 2026. PMID: 41687810. doi:10.1016/j.chest.2026.01.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。